Unfortunately, the very encouraging results obtained by testing different experimental antiangiogenic strategies in pre-clinical studies, showing at least partial if not quite significant prevention of fibrogenic progression, were not reproduced in clinical trials (extensively reviewed in References [ 8 , 9 , 10 , 27 , 28 , 29 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ]).
1
—
—